NanoEcho AB announces today that the name NanoEcho® and the company’s logo have been registered and granted trademark protection in all European Union member states. This dual registration is an important milestone to strengthen NanoEcho’s trademark portfolio and increase the company’s competitiveness ahead of commercial launches.
NanoEcho AB has signed a new letter of intent with us4us Ltd. regarding continued collaboration on the product development that was initiated with a letter of intent in July 2022. The collaboration is focused on the development of the next-generation ultrasound scanner module.
NanoEcho has been awarded a grant from the SME (Small and Medium Enterprises) -fund within the European Union Intellectual Property Office to cover initial fees related to a new patent application and trademark protection. These grants are provided to support the management of intellectual property assets for European SMEs.
NanoEcho strengthens the organization by hiring Ulrika Axelsson as responsible for the company’s clinical operations. Ulrika will be part of the company’s executive management team and will, among other things, be responsible for planning and carrying out the company’s clinical studies, with the goal of getting market approval for NanoEcho’s system for rectal cancer diagnostics.
NanoEcho welcomes new shareholders when one of the company’s previous main owners, Cardeon AB, has sold its holdings in the company. NanoEcho’s CEO Linda Persson has actively participated in the process through several national and international presentations to potential investors and has also been available for discussions and questions. The sales process has been handled entirely by Cardeon. The shares have mainly been acquired by long-term investors and foundations. A small share has also been sold through an ongoing distribution to Cardeon’s shareholders.
NanoEcho’s innovative method aims to address an urgent global need for more reliable rectal cancer staging. The method is intended to enable the mapping of lymphatic cancer spread prior to surgery – an important marker for the cancer’s progression. This mapping would make it possible to avoid surgery with high risk of complications. The basic patent for the method, previously granted in Japan, has now also been granted in Europe and South Korea.